According to Zhitong Finance App, Junshi Biotech (01877) announced that in the first three quarters of 2026, operating income was 2,513 billion yuan, up 39.18% year on year; net loss attributable to shareholders of listed companies was 149 million yuan, a year-on-year narrowing 75% year on year; basic loss per share was 0.15 yuan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.